We were honored to welcome team members from Esperion, a global biopharmaceutical company, to this year\u2019s NYC Awards Night. Representing the company were Betty Swartz, Chief Business Officer; Amy Wilson, Chief Compliance Officer; Donna Florio, Head of Field Reimbursement and Access Strategy; Maggie Glassman, Executive Director, Market Access; Evelyn Sarnes, Executive Director, Health Economics and Outcomes Research; and Lisa Schafer, VP, Head of Marketing.<\/p>\n
Esperion Therapeutics is focused on cardiovascular disease management, with two treatments approved in both the U.S. and Europe based on a unique mechanism of action. The company continues to evolve through commercial execution, international partnerships and collaborations, and advancement of its pre-clinical pipeline, with a scientific team leading the investigation of ACLY biology having brought the first ACLY inhibitor to market.\u00a0<\/a><\/p>\n Thanks to the Esperion team for joining us in New York for this year\u2019s event.<\/p>\n